Borkar, N., Xia, D., Holm, R., Gan, Y., Müllertz, A., Yang, M., Mu, H., Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium. Eur. J. Pharm. Sci. 51 (2014), 204–210.
Brouwers, J., Brewster, M.E., Augustijns, P., Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J. Pharm. Sci. 98 (2009), 2549–2572.
Butler, W.C.G., Bateman, S.R., A flow-through dissolution method for a two component drug formulation where the actives have markedly differing solubility properties. Int. J. Pharm. 173 (1998), 211–219.
Chiou, W.L., Riegelman, S., Oral absorption of griseofulvin in dogs: increased absorption viasolid dispersion in polyethylene glycol 6000. J. Pharm. Sci. 59 (1970), 937–942.
Convention, U.S., The dissolution procedure: development and validation. 29, T.n.F. The United States Pharmacopoeia, 34, 2011, United Book Press, Baltimore, MD, 624–630.
Devraj, R., Williams, H.D., Warren, D.B., Mohsin, K., Porter, C.J.H., Pouton, C.W., In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine. Eur. J. Pharm. Sci. 49 (2013), 748–760.
Do, T.T., Van Speybroeck, M., Mols, R., Annaert, P., Martens, J., Van Humbeeck, J., Vermant, J., Augustijns, P., Van den Mooter, G., The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. Int. J. Pharm. 414 (2011), 118–124.
Griffin, B.T., Kuentz, M., Vertzoni, M., Kostewicz, E.S., Fei, Y., Faisal, W., Stillhart, C., O'Driscoll, C.M., Reppas, C., Dressman, J.B., Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate. Eur. J. Pharm. Biopharm. 86 (2014), 427–437.
Grundy, J.S., Anderson, K.E., Rogers, J.A., Foster, R.T., Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J. Control. Release 48 (1997), 1–8.
Grundy, J.S., Anderson, K.E., Rogers, J.A., Foster, R.T., Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test. J. Control. Release 48 (1997), 9–17.
Guichard, J.P., Levy-Prades Sauron, R., A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr. Ther. Res. 54 (1993), 610–614.
Guivarc'h, P.H., Vachon, M.G., Fordyce, D., A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin. Ther. 26 (2004), 1456–1469.
Hanafy, A., Spahn-Langguth, H., Vergnault, G., Grenier, P., Tubic Grozdanis, M., Lenhardt, T., Langguth, P., Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev. 59 (2007), 419–426.
Hens, B., Brouwers, J., Corsetti, M., Augustijns, P., Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential. Eur. J. Pharm. Sci. 77 (2015), 40–47.
Juenemann, D., Jantratid, E., Wagner, C., Reppas, C., Vertzoni, M., Dressman, J.B., Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur. J. Pharm. Biopharm. e.V 77 (2011), 257–264.
Katchen, B., Symchowicz, S., Correlation of dissolution rate and griseofulvin absorption in man. J. Pharm. Sci. 56 (1967), 1108–1111.
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 420 (2011), 1–10.
Kinget, R., De Greef, H., In vitro assessment of drug release from semi-solid lipid matrices. Eur. J. Pharm. Sci. 3 (1995), 105–111.
Kollipara, S., Gandhi, R.K., Pharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations. Acta Pharm. Sin. B 4 (2014), 333–349.
Ling, H., Luoma, J.T., Hilleman, D., A review of currently available fenofibrate and fenofibric acid formulations. Cardiol. Res. 4 (2013), 47–55.
Long, M., Chen, Y., Chapter 14 – Dissolution Testing of Solid Products, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. 2009, Academic Press, San Diego, 319–340.
Lue, B.-M., Nielsen, F.S., Magnussen, T., Schou, H.M., Kristensen, K., Jacobsen, L.O., Müllertz, A., Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur. J. Pharm. Biopharm. 69 (2008), 648–657.
Miller, D., Spence, J.D., Clinical pharmacokinetics of Fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34 (1998), 155–162.
Mu, H., Holm, R., Müllertz, A., Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm. 453 (2013), 215–224.
O'Shea, J.P., Faisal, W., Ruane-O'Hora, T., Devine, K.J., Kostewicz, E.S., O'Driscoll, C.M., Griffin, B.T., Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments. Eur. J. Pharm. Biopharm. 96 (2015), 207–216.
Pharmacopoeia, E., Recommendations on Methods for Dosage Forms Testing, European Pharmacopoeia Druckerei C. 2010, H. Beck, Nördlingen, Germany, 665–667.
Phillips, D.J., Pygall, S.R., Cooper, V.B., Mann, J.C., Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J. Pharm. Pharmacol. 64 (2012), 1549–1559.
Pillay, V., Fassihi, R., A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug. Pharm. Res. 16 (1999), 333–337.
Posti, J., Speiser, P.P., Sink conditions in the flow-through cell during dissolution. Int. J. Pharm. 5 (1980), 101–107.
Sauron, R., Wilkins, M., Jessent, V., Dubois, A., Maillot, C., Weil, A., Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int. J. Clin. Pharmacol. Ther. 44 (2006), 64–70.
Shi, Y., Gao, P., Gong, Y., Ping, H., Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption. Mol. Pharm. 7 (2010), 1458–1465.
Sonet, B., Vanderbist, F., Streel, B., Houin, G., Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers. Arzneimittelforschung 52 (2002), 200–204.
Streel, B., Hubert, P., Ceccato, A., Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 742 (2000), 391–400.
Symchowicz, S., Katchen, B., Griseofulvin absorption in man after single and repeated treatments and its correlation with dissolution rates. J. Pharm. Sci. 57 (1968), 1383–1386.
Thomas, N., Richter, K., Pedersen, T., Holm, R., Müllertz, A., Rades, T., In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate. AAPS J. 16 (2014), 539–549.
US Department of Health and Human Services, F.D.A., Center for Drug Evaluation and Research, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. 1997.
Vangani, S., Li, X., Zhou, P., Del-Barrio, M.-A., Chiu, R., Cauchon, N., Gao, P., Medina, C., Jasti, B., Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system. Clin. Res. Regul. Aff. 26 (2009), 8–19.
Verbeeck, R.K., De Niet, S., Lebrun, S., Tremege, M., Rennie, T.W., Coffiner, M., Streel, B., Cahay, B., The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions. J. Pharm. Pharm. Sci. 18 (2015), 61–67.
Williams, H., Sassene, P., Kleberg, K., Calderone, M., Igonin, A., Jule, E., Vertommen, J., Blundell, R., Benameur, H., Müllertz, A., Pouton, C., Porter, C.H., Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations. Pharm. Res. 30 (2013), 3059–3076.
